Pyrazole Amide Derivatives as P2X7 Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain, inflammation, and neurodegenerative disorders, particularly those involving the P2X7 receptor, are inadequate in effectively modulating receptor function and antagonizing ATP effects, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of heterocyclic amide derivatives that specifically modulate P2X7 receptor function by acting as antagonists, capable of competing with ATP, thereby inhibiting receptor activation and associated inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for pain and inflammation, then they provide some therapeutic effect, but they fail to effectively modulate P2X7 receptor function and antagonize ATP effects
Solution Approach 1:
The patent modifies molecular parameters of the compounds by varying substituents at different positions (R1 at position 1, R2 at position 3, R3 at position 5 of the pyrazole ring, and R4 on the benzamide group) to optimize P2X7 receptor antagonistic activity. This systematic parameter optimization enables effective ATP effect antagonism while maintaining therapeutic reliability for pain and inflammation treatment.
2Reliability
If P2X7 receptor antagonists are developed to specifically block ATP effects, then they provide targeted therapeutic action, but they require complex molecular structures with multiple substituents
Solution Approach 1:
The patent designs a universal molecular scaffold (1-substituted-3,5-disubstituted-1H-pyrazole-4-carboxamides) that can perform multiple functions: P2X7 receptor antagonism, ATP effect blocking, and anti-inflammatory action. The core structure remains consistent while allowing substituent variations to fine-tune activity, reducing overall molecular complexity while maintaining targeted therapeutic action.
3Reliability
If heterocyclic amide derivatives are designed with specific substituents to enhance P2X7 antagonism, then they achieve better therapeutic outcomes, but they become more difficult to synthesize
Solution Approach 1:
The patent divides the molecular synthesis into separate stages: first preparing the core pyrazole-4-carboxamide structure, then introducing substituents R1, R2, R3, and R4 in subsequent steps. This segmented approach allows each substitution step to be optimized independently, enhancing therapeutic outcomes while making the overall synthesis more manageable and scalable for manufacturing.
Data Source
AI summary
The present invention relates to novel pyrazole derivatives of formula (I) which bind to the P2X7 receptor and are capable of interfering with the effects of ATP at the P2X7 receptor, and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.